Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Lanner introduces LEC-6041 industrial cyber security gateway November 12, 2018 India starts exporting petroleum products to Myanmar September 4, 2017 Prices of imported mobile phones, parts to rise as govt imposes 10% customs duty July 1, 2017